VARTISANCopy

• DRUGBANK - Valsartan
• indication:

  For the treatment of hypertension.

• pharmacology:

• mechanism:

  Valsartan competes with angiotensin II for binding at the AT<sub>1</sub> receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.

• toxicity:

• absorprion:

  Absolute bioavailability = 23% with high variability

• halflife:

  The initial phase t<sub>1/2 α</sub> is < 1 hour while the terminal phase t<sub>1/2 β</sub> is 5-9 hours.

• roouteelimination:

• volumedistribution:

  * 17 L

• clearance:

  * 2 L/h [IV administration] * 4.5 L/h [heart Failure patients receiving oral administration 40 to 160 mg twice a day]